Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IPSC NASDAQ:KALA NASDAQ:LRMR NASDAQ:PRTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPSCCentury Therapeutics$2.34+2.2%$2.33$0.44▼$3.04$413.01M1.55963,360 shs745,802 shsKALAKALA BIO$0.12+2.7%$0.23$0.10▼$20.60$104.20M-2.233.49 million shs1.26 million shsLRMRLarimar Therapeutics$4.15+3.5%$4.79$1.73▼$6.42$416.57M0.911.42 million shs2.42 million shsPRTCPureTech Health$17.01+1.9%$16.81$14.50▼$19.92$413.95M1.1510,716 shs18,676 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPSCCentury Therapeutics+2.18%+6.36%+6.85%+40.12%+340.68%KALAKALA BIO+4.64%+5.21%-33.43%-71.15%-96.66%LRMRLarimar Therapeutics+3.49%-4.38%-17.82%+35.18%+97.62%PRTCPureTech Health+1.92%-2.24%+9.14%-5.94%-1.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPSCCentury Therapeutics$2.34+2.2%$2.33$0.44▼$3.04$413.01M1.55963,360 shs745,802 shsKALAKALA BIO$0.12+2.7%$0.23$0.10▼$20.60$104.20M-2.233.49 million shs1.26 million shsLRMRLarimar Therapeutics$4.15+3.5%$4.79$1.73▼$6.42$416.57M0.911.42 million shs2.42 million shsPRTCPureTech Health$17.01+1.9%$16.81$14.50▼$19.92$413.95M1.1510,716 shs18,676 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPSCCentury Therapeutics+2.18%+6.36%+6.85%+40.12%+340.68%KALAKALA BIO+4.64%+5.21%-33.43%-71.15%-96.66%LRMRLarimar Therapeutics+3.49%-4.38%-17.82%+35.18%+97.62%PRTCPureTech Health+1.92%-2.24%+9.14%-5.94%-1.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPSCCentury Therapeutics 2.43Hold$4.2581.62% UpsideKALAKALA BIO 2.00Hold$20.3817,602.00% UpsideLRMRLarimar Therapeutics 3.10Buy$16.50297.59% UpsidePRTCPureTech Health 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest KALA, LRMR, IPSC, and PRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026LRMRLarimar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/21/2026IPSCCentury Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $5.004/6/2026IPSCCentury Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026KALAKALA BIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/25/2026LRMRLarimar Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/20/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $13.003/13/2026IPSCCentury Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetMarket Perform$2.003/12/2026IPSCCentury Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/3/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$11.00 ➝ $12.002/25/2026IPSCCentury Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPSCCentury Therapeutics$109.16M3.87$0.01 per share172.18$1.82 per share1.29KALAKALA BION/AN/AN/AN/A$0.71 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/APRTCPureTech Health$4.66M88.87N/AN/A$12.65 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPSCCentury Therapeutics-$9.58M-$0.14N/AN/AN/AN/A-1.43%-1.05%5/21/2026 (Estimated)KALAKALA BIO-$26.98M-$3.33N/AN/AN/AN/A-12,971.16%-90.83%N/ALRMRLarimar Therapeutics-$165.67M-$2.21N/AN/AN/AN/A-137.70%-101.43%5/7/2026 (Estimated)PRTCPureTech Health-$109.74MN/AN/AN/AN/AN/AN/AN/AN/ALatest KALA, LRMR, IPSC, and PRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026IPSCCentury Therapeutics-$0.15N/AN/AN/A$2.87 millionN/A5/7/2026Q1 2026LRMRLarimar Therapeutics-$0.53N/AN/AN/AN/AN/A4/15/2026Q4 2025KALAKALA BIO-$0.17$0.86+$1.03$0.86N/AN/A4/10/2026H2 2025PRTCPureTech HealthN/A-$1.35N/A-$1.35N/A$1.40 million3/19/2026Q4 2025LRMRLarimar Therapeutics-$0.43-$0.73-$0.30-$0.73N/AN/A3/12/2026Q4 2025IPSCCentury Therapeutics-$0.29-$0.25+$0.04-$0.25($0.08) millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIPSCCentury TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPSCCentury TherapeuticsN/A5.975.97KALAKALA BION/A3.813.81LRMRLarimar TherapeuticsN/A2.192.19PRTCPureTech HealthN/A6.596.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPSCCentury Therapeutics50.20%KALAKALA BIO24.61%LRMRLarimar Therapeutics91.92%PRTCPureTech Health0.04%Insider OwnershipCompanyInsider OwnershipIPSCCentury Therapeutics4.37%KALAKALA BIO2.24%LRMRLarimar Therapeutics4.50%PRTCPureTech Health5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPSCCentury Therapeutics170180.35 million172.47 millionOptionableKALAKALA BIO30929.49 million908.67 millionNot OptionableLRMRLarimar Therapeutics30103.88 million99.21 millionOptionablePRTCPureTech Health10024.34 million23.05 millionNot OptionableKALA, LRMR, IPSC, and PRTC HeadlinesRecent News About These CompaniesPureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPOMay 1, 2026 | proactiveinvestors.co.ukPureTech Health H2 Earnings Call HighlightsApril 29, 2026 | marketbeat.comPureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPSApril 29, 2026 | marketbeat.comPureTech Announces Annual Results for Year Ended December 31, 2025April 29, 2026 | businesswire.comPureTech Health (PRTC) Expected to Announce Earnings on WednesdayApril 22, 2026 | marketbeat.comPureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 30.8% in MarchApril 15, 2026 | marketbeat.comPureTech Health: Notice of ResultsApril 13, 2026 | businesswire.comPureTech Gains on ResultsApril 2, 2026 | baystreet.caPureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care MedicineApril 2, 2026 | businesswire.comPureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in HumansMarch 25, 2026 | businesswire.comPureTech to Present at the Leerink Partners Global Healthcare ConferenceFebruary 25, 2026 | businesswire.comPureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary FibrosisFebruary 19, 2026 | businesswire.comPureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comPureTech to Present at 44th Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2026 | finance.yahoo.comPureTech CEO to present at JP Morgan Healthcare ConferenceJanuary 6, 2026 | msn.comPureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the companyJanuary 3, 2026 | finance.yahoo.comPureTech Appoints Robert Lyne as Chief Executive OfficerDecember 18, 2025 | businesswire.comPeel Hunt Limited reiterates PureTech Health plc - Depositary Receipt (PRTC) buy recommendationDecember 16, 2025 | msn.comPureTech stock falls after FDA meeting on IPF drugDecember 8, 2025 | in.investing.comPureTech Health completes LYT-100 end-of-phase 2 meeting with FDADecember 8, 2025 | msn.comPureTech slides after FDA meeting outlines next steps for IPF programDecember 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALA, LRMR, IPSC, and PRTC Company DescriptionsCentury Therapeutics NASDAQ:IPSC$2.34 +0.05 (+2.18%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$2.36 +0.02 (+0.85%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.KALA BIO NASDAQ:KALA$0.12 +0.00 (+2.68%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$0.12 +0.00 (+0.78%) As of 08:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Larimar Therapeutics NASDAQ:LRMR$4.15 +0.14 (+3.49%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$4.20 +0.05 (+1.30%) As of 08:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.PureTech Health NASDAQ:PRTC$17.01 +0.32 (+1.92%) Closing price 05/6/2026 03:49 PM EasternExtended Trading$17.57 +0.56 (+3.29%) As of 08:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
